MAP2K7 and neoplasm: Triple therapy with T-VEC, MEK inhibition, and an anti-PD-1 antibody was then found to further augment immune response with over 80% complete tumor eradication from baseline and increased overall survival without overt toxicity in pre-clinical murine models [47, 48].